Pyrazomycin
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-02590 |
| CAS | 30868-30-5 |
| Molecular Weight | 259.22 |
| Molecular Formula | C9H13N3O6 |
| Purity | ≥ 97% |
Online Inquiry
Description
Pyrazomycin is an antibiotic produced by Str. candidus NRRL 3601. In the culture of monolayer cells, the minimum inhibitory concentration of vaccinia virus is 2 μg/mL, which can also inhibit measles and herpes simplex. In mice, intraperitoneal, subcutaneous, oral and skin application can reduce the pathological changes of vaccinia. Pyrazomycin is a competitive inhibitor of pyrimidine nucleoside metabolism.
Specification
| Synonyms | Pyrazofurin; Pirazofurin; Pirazofurina |
| IUPAC Name | 3-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1H-pyrazole-5-carboxamide |
| Canonical SMILES | C(C1C(C(C(O1)C2=NNC(=C2O)C(=O)N)O)O)O |
| InChI | InChI=1S/C9H13N3O6/c10-9(17)4-6(15)3(11-12-4)8-7(16)5(14)2(1-13)18-8/h2,5,7-8,13-16H,1H2,(H2,10,17)(H,11,12)/t2-,5-,7-,8+/m1/s1 |
| InChI Key | XESARGFCSKSFID-FLLFQEBCSA-N |
Properties
| Antibiotic Activity Spectrum | viruses |
| Boiling Point | 584.397°C at 760 mmHg |
| Melting Point | 108-113°C |
| Density | 1.786 g/cm3 |
Reference Reading
1.Calcium oxalate crystals increased enolase-1 secretion from renal tubular cells that subsequently enhanced crystal and monocyte invasion through renal interstitium.
Chiangjong W1,2,3, Thongboonkerd V1,3. Sci Rep. 2016 Apr 5;6:24064. doi: 10.1038/srep24064.
Calcium oxalate monohydrate (COM) crystals cause kidney stone disease by still unclear mechanisms. The present study aimed to characterize changes in secretion of proteins from basolateral compartment of renal tubular epithelial cells after exposure to COM crystals and then correlated them with the stone pathogenesis. Polarized MDCK cells were cultivated in serum-free medium with or without 100 μg/ml COM crystals for 20 h. Secreted proteins collected from the lower chamber (basolateral compartment) were then resolved in 2-D gels and visualized by Deep Purple stain (n = 5 gels/group). Spot matching and intensity analysis revealed six protein spots with significantly altered levels in COM-treated samples. These proteins were then identified by tandem mass spectrometry (Q-TOF MS/MS), including enolase-1, phosphoglycerate mutase-1, actinin, 14-3-3 protein epsilon, alpha-tubulin 2, and ubiquitin-activating enzyme E1. The increased enolase-1 level was confirmed by Western blot analysis.
2.Comparison of the crystal structures of the potent anticancer and anti-angiogenic agent regorafenib and its monohydrate.
Sun MY1, Wu SX1, Zhou XB1, Gu JM2, Hu XR2. Acta Crystallogr C Struct Chem. 2016 Apr 1;72(Pt 4):291-6. doi: 10.1107/S2053229616003727. Epub 2016 Mar 10.
Regorafenib {systematic name: 4-[4-({[4-chloro-3-(trifluoromethy)phenyl]carbamoyl}amino)-3-fluorophenoxy]-1-methylpyridine-2-carboxamide}, C21H15ClF4N4O3, is a potent anticancer and anti-angiogenic agent that possesses various activities on the VEGFR, PDGFR, raf and/or flt-3 kinase signaling molecules. The compound has been crystallized as polymorphic form I and as the monohydrate, C21H15ClF4N4O3·H2O. The regorafenib molecule consists of biarylurea and pyridine-2-carboxamide units linked by an ether group. A comparison of both forms shows that they differ in the relative orientation of the biarylurea and pyridine-2-carboxamide units, due to different rotations around the ether group, as measured by the C-O-C bond angles [119.5 (3)° in regorafenib and 116.10 (15)° in the monohydrate]. Meanwhile, the conformational differences are reflected in different hydrogen-bond networks. Polymorphic form I contains two intermolecular N-H...O hydrogen bonds, which link the regorafenib molecules into an infinite molecular chain along the b axis.
3.[Comparison of the modified Hodge test and the Carba NP test for detection of carbapenemases in Enterobacteriaceae isolates].
Bayramoğlu G1, Uluçam G, Gençoğlu Özgür Ç, Kılıç AO, Aydın F. Mikrobiyol Bul. 2016 Jan;50(1):1-10.
A rapid, practical, and accurate identification of carbapenemase-producing Enterobacteriaceae isolates is crucial for the implementation of appropriate infection control measures and proper treatment of the infections. For this purpose, a large number of phenotypic test methods have been developed, although none has 100% sensitivity and specificity. Variations in sensitivity and specificity of these tests based on the type of beta-lactamase enzymes carried by that isolates might result in differences between regions and countries. The aim of this study was to compare the performances of widely used modified Hodge test (MHT) and Carbapenemase Nordmann-Poirel (Carba NP) test in the detection of carbapenemases in Enterobacteriaceae family members. A total of 65 Enterobacteriaceae isolates (43 bla(OXA-48), 10 bla(VIM), 9 bla(IMP), 1 bla(NDM-1), 1 bla(KPC-2) and 1 bla(OXA-48)+bla(VIM) carrying strains) that showed decreased sensitivity to at least one carbapenem (ertapenem, imipenem or meropenem), and carriage of carbapenemase gene confirmed by polymerase chain reaction (PCR), were included in the study.
4.Multivariate Analyses of Urinary Calculi Composition: A 13-Year Single-Center Study.
Yang X1, Zhang C1, Qi S1, Zhang Z1, Shi Q1, Liu C1, Yang K1, Du E1, Li N1, Shi J1, Xu Y1. J Clin Lab Anal. 2016 Apr 13. doi: 10.1002/jcla.21950. [Epub ahead of print]
BACKGROUND: The incidence and prevalence of urinary stone are increasing throughout the world. Compared to the past, recent demographics of patient with urolithiasis compositions are strikingly different. Furthermore, recent clinical studies implied that seasonal cyclicity might influence the distribution of stone composition.
Recommended Products
| BBF-01826 | Deoxymannojirimycin | Inquiry |
| BBF-05862 | Epirubicin | Inquiry |
| BBF-02642 | Lactonamycin | Inquiry |
| BBF-01693 | Doxorubicin EP Impurity A (Daunorubicin) | Inquiry |
| BBF-00677 | 3-Amino-3-deoxy-D-glucose | Inquiry |
| BBF-01825 | Loganin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
